%D9%81%D9%84%D9%88%D8%B3%D9%8A%D8%AA%D9%88%D8%B2%D9%8A%D9%86%D9%81%D9%84%D9%88%D8%B3%DB%8C%D8%AA%D9%88%D8%B2%DB%8C%D9%86Category:FluorocytosineFflwcytosin5-FluorcytosinFlucytosineFlucitosina%D9%81%D9%84%D9%88%D8%B3%DB%8C%D8%AA%D9%88%D8%B2%DB%8C%D9%86FlusytosiiniFlucytosineFlusitosinFlucitosina%E3%83%95%E3%83%AB%E3%82%B7%E3%83%88%E3%82%B7%E3%83%B3%E0%AC%AB%E0%AD%8D%E0%AC%B2%E0%AD%81%E0%AC%B8%E0%AC%BF%E0%AC%9F%E0%AD%8B%E0%AC%B8%E0%AC%BF%E0%AC%A8FluorocytozynaFlucitosinaFlucitozin%C4%83FlucitozinFlucitozin%D0%A4%D0%BB%D1%83%D1%86%D0%B8%D1%82%D0%BE%D0%B7%D0%B8%D0%BDFlucytosineQ238490%E6%B0%9F%E8%83%9E%E5%98%A7%E5%95%B6
about
P3781
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain TumorPhase I/II Study of APS001F With Flucytosine and Maltose in Solid TumorsSafety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal InfectionStudy of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade GliomasA Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant GliomaA Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of CareGenetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade GliomasThe Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade GliomaTrial of TG4023 Combined With Flucytosine in Liver TumorsEfficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDSSafety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma PatientsA Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan AfricaSafety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal MeningitisA Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal MeningitisA Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisDexamethasone in Cryptococcal MeningitisMulti-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal MeningitisA Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal MeningitisAmB Dose for Cryptococcal MeningitisTesting the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed GlioblastomaA Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal TractStudy of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal CancerSafety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid TumorsA Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
P4844
Systemic antifungal agents.Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells.Caspofungin irrigation through percutaneous calicostomy catheter combined with oral flucytosine to treat fluconazole-resistant symptomatic candiduria.Flucytosine, a major antifungal agent.Comparison of MICs of fluconazole and flucytosine when dissolved in dimethyl sulfoxide or water.Insect population control using female specific pro-drug activation.In vitro postantifungal effect, adhesion traits and haemolysin production of Candida dubliniensis isolates following exposure to 5-fluorocytosine.Sequential Photodynamic Therapy with Phthalocyanine Encapsulated Chitosan-Tripolyphosphate Nanoparticles and Flucytosine Treatment against
P921
Q1470140-686489F6-B00A-42B3-9CAB-74E815F10B08Q18967011-47A23B89-93C0-41F4-AFDB-8D7767D1BA30Q18967417-12B3DEF1-EC44-409F-BACA-7284A8C097D1Q18967594-D813AF8F-DE0F-4DC5-BF17-46FCEA2529EEQ259626-709D597C-57D6-4140-B86F-CE94EB307696Q2726043-E4C24349-97E6-4847-8E5A-C1705D739DD1Q273510-074CF225-7274-40E2-9D16-3D60F8D955D8Q273510-BF62A319-91BC-4340-9BBD-4C2E658CAFCFQ464067-6D726868-534C-474A-A09E-0C1135BD9A2DQ48143-099E3B4F-B561-4148-AEDA-EEDC3C9AEDDF
P2176
Q61955626-5ED14A2E-3618-4A98-A7E0-FBAB4775ACADQ63316134-9115A027-7D38-467D-9227-8BBBA7D64052Q63316237-E62415F2-42A6-4CF5-91B0-08CBEAA6C85CQ63597846-2C56FC6F-4012-4EEB-AC80-1FC2014DE3B8Q63830903-7A800C1F-3F63-4D6B-8344-1DFF5DA19709Q63835699-643CC0E7-BE53-4528-8DC5-9B15F8EA2D83Q64216592-017A75CE-136C-4053-AF0D-973A05B3C76CQ64350727-5D38B9CF-E990-4B99-B2A6-D1D5522DCA78Q64396534-F62EF58D-126B-4142-960A-DE8290D56D49Q64662862-69B2F3DA-A4E6-4E59-9EF0-DC6551BD3551Q64680625-AAD850BA-C43D-4012-A5F8-4AE83F1BF224Q64816897-AA5CE133-4B0A-4371-AE67-0F9652A9E804Q65316812-59DB6FDD-91A4-4D2D-8D62-9BB147E56518Q65373991-C83058EE-E98C-4EBC-9385-186033F68ACBQ66039842-1C3A6EDD-A73C-467F-95DE-91B10AACAF26Q66040258-916E908F-0F5B-4366-8984-2683E85BAA14Q66040452-8BB2BEC1-3CA9-4A48-B372-EC3FB30A22ECQ66040490-062C4BCA-D1C9-4863-907A-A98694D49155Q66040942-66BE3D05-4114-4604-BDDA-7A0DF2F314B3Q66041010-FFDCD8F2-9FDB-4408-82E2-DC8D4C7F806CQ66041079-A4E8D717-A408-4090-A85B-EF00BCC9BA87Q74273206-0538367E-C235-44B5-A4FC-EE048A225A4DQ74280199-86AD796B-0AEA-4CAF-86A3-F3F894F206DAQ74282293-C481E789-B554-4CCF-B3E9-4CB020373DFBQ79110513-66D18315-0F2B-409D-BE39-F8FE00849CBEQ79110861-3224F421-0B57-4165-8B11-64897AC0C638Q87076999-A712FD09-45B8-4149-ADBA-42B4D4083DE8Q89153439-EF0CABFA-4C6C-4F5B-B31D-4CD471BD9789
P4844
Q34344425-469F2880-7FFE-4CFF-A76D-9DCF0C512B0AQ38717713-740C4FC9-20CC-41C6-A26B-A5E57708C5DDQ41505052-23661D31-9D4E-4533-8F86-3B30F07B327AQ42008481-9C7CBC2A-70EB-4D2C-941E-2B47CD9E24B2Q42071054-9DDB1CCA-C3A4-4C09-8C2C-D5FB7352256EQ44761757-CF5797AA-09A0-49EE-9F87-6DD03B1A4B41Q46696611-E3A35260-D962-40BC-9F65-B82AD0071F34Q61806421-3C1C5BAF-7DAD-42F2-ACDD-E82932DDEA1C
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
5-Fluorcytosin
@de
5-fluorocytosine
@en
Flucitosina
@ca
Flucitozin
@sh
Flucitozină
@ro
Flucytosine
@nl
Flucytosine
@vi
Fluorocitosina
@es
Fluorocitosina
@pt
Flusitosin
@id
type
label
5-Fluorcytosin
@de
5-fluorocytosine
@en
Flucitosina
@ca
Flucitozin
@sh
Flucitozină
@ro
Flucytosine
@nl
Flucytosine
@vi
Fluorocitosina
@es
Fluorocitosina
@pt
Flusitosin
@id
altLabel
5-FC
@en
5-Fluorocystosine
@en
5-Fluorocytosin
@en
5-Fluorocytosine
@en
5-Flurocytosine
@en
5-flucitosina
@ca
Alcobon
@en
Ancoban
@cy
Ancoban
@en
Ancobon (tn)
@cy
prefLabel
5-Fluorcytosin
@de
5-fluorocytosine
@en
Flucitosina
@ca
Flucitozin
@sh
Flucitozină
@ro
Flucytosine
@nl
Flucytosine
@vi
Fluorocitosina
@es
Fluorocitosina
@pt
Flusitosin
@id